1. Understanding generic drugs. US Food and Drug Administration, Silver Spring, 2012. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/default.htm . Accessed 5 Apr 2013.
2. Mastan S, Latha TB, Ajay S. The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence studies—an overview. Comp Eff Res. 2011;1:1–25. doi: 10.2147/CER.S15861 .
3. Kanfer I. Introduction. In: Kanfer I, Shargel L, editors. Generic drug product development, international regulatory requirements for bioequivalence. New York: Informa Healthcare; 2010. p. 1–16.
4. Electronic orange book. US Food and Drug Administration, Silver Spring. 2012. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf . Accessed 5 Apr 2013.
5. Guideline, the investigation of bioequivalence. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA) 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf . Accessed 5 Apr 2013.